Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (761)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (412)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2092)
  2. Meeting Abstract (2072)
  3. Book Section (181)
  4. Review (88)
  5. Editorial (80)
  6. Guidelines (36)
  7. Correspondence (24)
  8. Book Whole (17)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (761)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (67)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1667)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4614)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
    Meeting Abstract

    Skoulidis, F.; Li, B. T.; Hochmair, M. J.; Govindan, R.; Vincent, M.; Van Der Wekken, A. J.; Reguart Aransay, N.; O'Byrne, K. J.; Girard, N.; Griesinger, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
    Meeting Abstract

    Skoulidis, F.; Jabbour, S.; Garon, E. B.; Iyengar, P.; Scagliotti, G.; Ferrer, L.; Etchepare, G.; Gallinato, O.; Faure, J.; Bernard, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Murray, J. C.; Huang, Q.; Hu, C.; Curran, E.; Wong, C.; Glatz, L.; Wang, T.; Hasan, A.; Villaruz, L.; Schoenfeld, A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
    Meeting Abstract

    Krebs, M. G.; Lu, S.; Fan, Y.; Yu, Y.; Drilon, A. E.; Siena, S.; Xue, C.; Bradley, D.; Hu, X.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
    Meeting Abstract

    Solomon, B. J.; Drilon, A. E.; Wirth, L. J.; Szpurka, A.; Rao, X.; Massey, A. C.; Barker, S.; Wright, J.; Won, H.; Cabanillas, M. E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
    Meeting Abstract

    Di Federico, A.; Chen, M. F.; Pagliaro, A.; Ogliari, F. R.; Stockhammer, P.; Aldea, M.; Grant, M.; De Giglio, A.; Alessi, J. V.; Pecci, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
    Meeting Abstract

    Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, S. W.; Han, J. Y.; Kim, C.; Shim, B.; Ricordel, C.; Drilon, A. E.; Pujol, J. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
    Meeting Abstract

    Drilon, A. E.; Lin, J. J.; Johnson, M. L.; Baik, C. S.; Paz-Ares, L. G.; Besse, B.; Mazieres, J.; Swalduz, A.; Minchom, A. R.; Reuss, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
    Meeting Abstract

    Passaro, A.; Yu, H. A.; Nguyen, D.; Lee, V. H. F.; Soo, R. A.; Kim, S. H.; Daga, H.; Tan, D. S. W.; Kim, S. W.; Juan Vidal, O. J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
    Meeting Abstract

    Besse, B.; Drilon, A. E.; Cho, B. C.; Camidge, D. R.; Neal, J.; Lin, C. C.; Liu, S. V.; Nagasaka, M.; Kao, S. C. H.; Felip, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save